Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer

References

• Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dorken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer. Eur J Cancer 2011; 47: 1676–1681
   PubMed Web of Science ®Google Scholar
• Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8: 82–92
   PubMed Web of Science ®Google Scholar
• Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946–3952
   PubMed Web of Science ®Google Scholar
• Heinrich S, Schafer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: Results of a prospective phase II trial. Ann Surg 2008; 248: 1014–1022
   PubMedGoogle Scholar
• Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study. Br J Cancer 2006; 94: 481–485
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825
   PubMed Web of Science ®Google Scholar
• Boeck S, Weigang-Kohler K, Fuchs M, Kettner E, Quietzsch D, Trojan J, et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: A multicenter phase II trial. Ann Oncol 2007; 18: 745–751
   PubMed Web of Science ®Google Scholar
• Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 2007; 73: 221–227
   PubMed Web of Science ®Google Scholar
• Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: Results of a phase II study. Cancer Invest 2008; 26: 47–52
   PubMed Web of Science ®Google Scholar
• Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, et al. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol 2008; 31: 145–150
   PubMed Web of Science ®Google Scholar
• Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs 2005; 23: 369–375
   PubMed Web of Science ®Google Scholar
• Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007; 25: 4787–4792
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Polyzos A, Stathopoulos GP, Tselepatiotis E, Christophylakis C, Kalbakis K, et al. A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 2006; 71: 159–163
   PubMed Web of Science ®Google Scholar
• Ulrich-Pur H, Raderer M, Verena Kornek G, Schull B, Schmid K, Haider K, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003; 88: 1180–1184
   PubMed Web of Science ®Google Scholar
• Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer 2008; 44: 2546–2554
   PubMed Web of Science ®Google Scholar
• Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002; 3: 487–497
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Li LF, Yang DP, LeBlanc JM. Cisplatin sensitization by concurrent mild hyperthermia in parental and mutant cell lines deficient in homologous recombination and non-homologous endjoining repair. Oncol Rep 2005; 14: 281–285
   PubMedGoogle Scholar
• Urano M, Wong KH, Reynolds R, Begley J. The advantageous use of hypoxic tumour cells in cancer therapy: Identical chemosensitization by metronidazole and misonidazole at moderately elevated temperatures. Int J Hyperthermia 1995; 11: 379–388
   PubMed Web of Science ®Google Scholar
• Wallner KE, DeGregorio MW, Li GC. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res 1986; 46: 6242–6245
   PubMed Web of Science ®Google Scholar
• Ohtsubo T, Saito H, Tanaka N, Matsumoto H, Sugimoto C, Saito T, et al. Enhancement of cisplatin sensitivity and platinum uptake by 40°C hyperthermia in resistant cells. Cancer Lett 1997; 119: 47–52
   PubMed Web of Science ®Google Scholar
• Adachi S, Kokura S, Okayama T, Ishikawa T, Takagi T, Handa O, et al. Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines. Int J Hyperthermia 2009; 25: 210–219
   PubMed Web of Science ®Google Scholar
• Haveman J, Rietbroek RC, Geerdink A, Van Rijn J, Bakker PJ. Effect of hyperthermia on the cytotoxicity of 2′,2′-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int J Cancer 1995; 62: 627–630
   PubMed Web of Science ®Google Scholar
• Van Bree C, Franken NA, Bakker PJ, Klomp-Tukker LJ, Barendsen GW, Kipp JB. Hyperthermia and incorporation of halogenated pyrimidines: Radiosensitization in cultured rodent and human tumor cells. Int J Radiat Oncol Biol Phys 1997; 39: 489–496
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study. Lancet Oncol 2010; 11: 561–570
   PubMed Web of Science ®Google Scholar
• Lagendijk JJ, Van Rhoon GC, Hornsleth SN, Wust P, De Leeuw AC, Schneider CJ, et al. ESHO quality assurance guidelines for regional hyperthermia. Int J Hyperthermia 1998; 14: 125–133
   PubMed Web of Science ®Google Scholar
• Bruggmoser G, Bauchowitz S, Canters R, Crezee H, Ehmann M, Gellermann J, et al. Quality assurance for clinical studies in regional deep hyperthermia. Strahlenther Onkol 2011; 187: 605–610
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247
   PubMed Web of Science ®Google Scholar
• Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, et al. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: A randomized multicenter phase III study (NEOPAC study). BMC Cancer 2008; 8: 82–92
   PubMedGoogle Scholar
• Yasuda M, Kondo M, Kokura S, Naito Y, Norimasa Y, Yoshikawa T. Comparison of concomitant gemcitabine chemotherapy and local hyperthermia, gemcitabine monochemotherapy, and local hyperthermia monotherapy for inoperable progressive pancreatic cancer. J Clin Oncol 2008; 26: abstr 15672
   Google Scholar
• Takagi T, Kokura S, Ishikawa T, Inui T, Isozaki Y, Oyamada H, Ando T, Naito Y, Handa O, Yoshikawa T, The effect of the combination therapy of hyperthermia and gemcitabine for the treatment of advanced inoperable pancreatic cancer. 10th International Congress on Hyperthermic Oncology, Munich, Germany, 9–12 April 2008. Abstr 8114380
   Google Scholar
• Bakshandeh-Bath A, Stoltz AS, Homann N, Wagner T, Stolting S, Peters SO. Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma. Anticancer Res 2009; 29: 3069–3077
   PubMed Web of Science ®Google Scholar
• Kakehi M, Ueda K, Mukojima T, Hiraoka M, Seto O, Akanuma A, et al. Multi-institutional clinical studies on hyperthermia combined with radiotherapy or chemotherapy in advanced cancer of deep-seated organs. Int J Hyperthermia 1990; 6: 719–740
   PubMed Web of Science ®Google Scholar
• Kouloulias VE, Nikita KS, Kouvaris JR, Golematis BC, Uzunoglu NK, Mystakidou K, et al. Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma. Eur J Cancer Care 2002; 11: 100–107
   PubMed Web of Science ®Google Scholar